H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Bicycle Therapeutics (BCYC – Research Report) today and set a price target of $25.00. The company’s shares closed last Friday at $17.30.
According to TipRanks.com, Chattopadhyay is a 5-star analyst with an average return of 18.3% and a 51.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics, and Molecular Partners AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bicycle Therapeutics with a $23.63 average price target.
The company has a one-year high of $19.79 and a one-year low of $6.24. Currently, Bicycle Therapeutics has an average volume of 45.82K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.